Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer

AUA/ASCO/ASTRO/SUO Guideline

Sam S. Chang, Bernard H. Bochner, Roger Chou, Robert Dreicer, Ashish M. Kamat, Seth P. Lerner, Yair Lotan, Joshua J. Meeks, Jeff M. Michalski, Todd M. Morgan, Diane Z. Quale, Jonathan E. Rosenberg, Anthony L. Zietman, Jeffrey M. Holzbeierlein

Research output: Contribution to journalArticle

126 Citations (Scopus)

Abstract

Purpose: This multidisciplinary, evidence-based guideline for clinically non-metastatic muscle-invasive bladder cancer focuses on the evaluation, treatment and surveillance of muscle-invasive bladder cancer guided toward curative intent. Materials and Methods: A systematic review utilizing research from the Agency for Healthcare Research and Quality as well as additional supplementation by the authors and consultant methodologists was used to develop the guideline. Evidence-based statements were based on body of evidence strengths Grade A, B or C and were designated as Strong, Moderate and Conditional Recommendations with additional statements presented in the form of Clinical Principles or Expert Opinions. Results: For the first time for any type of malignancy, the American Urological Association, American Society of Clinical Oncology, American Society for Radiation Oncology and Society of Urologic Oncology have formulated an evidence-based guideline based on a risk-stratified clinical framework for the management of muscle-invasive urothelial bladder cancer. This document is designed to be used in conjunction with the associated treatment algorithm. Conclusions: The intensity and scope of care for muscle-invasive bladder cancer should focus on the patient, disease and treatment response characteristics. This guideline attempts to improve a clinician's ability to evaluate and treat each patient, but higher quality evidence in future trials will be essential to improve level of care for these patients.

Original languageEnglish (US)
JournalJournal of Urology
DOIs
StateAccepted/In press - 2017

Fingerprint

Urinary Bladder Neoplasms
Guidelines
Muscles
Radiation Oncology
Health Services Research
Expert Testimony
Therapeutics
Consultants
Patient Care
Research
Neoplasms

Keywords

  • Cystectomy
  • Drug therapy
  • Radiotherapy
  • Urinary bladder neoplasms

ASJC Scopus subject areas

  • Urology

Cite this

Chang, S. S., Bochner, B. H., Chou, R., Dreicer, R., Kamat, A. M., Lerner, S. P., ... Holzbeierlein, J. M. (Accepted/In press). Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA/ASCO/ASTRO/SUO Guideline. Journal of Urology. https://doi.org/10.1016/j.juro.2017.04.086

Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer : AUA/ASCO/ASTRO/SUO Guideline. / Chang, Sam S.; Bochner, Bernard H.; Chou, Roger; Dreicer, Robert; Kamat, Ashish M.; Lerner, Seth P.; Lotan, Yair; Meeks, Joshua J.; Michalski, Jeff M.; Morgan, Todd M.; Quale, Diane Z.; Rosenberg, Jonathan E.; Zietman, Anthony L.; Holzbeierlein, Jeffrey M.

In: Journal of Urology, 2017.

Research output: Contribution to journalArticle

Chang, SS, Bochner, BH, Chou, R, Dreicer, R, Kamat, AM, Lerner, SP, Lotan, Y, Meeks, JJ, Michalski, JM, Morgan, TM, Quale, DZ, Rosenberg, JE, Zietman, AL & Holzbeierlein, JM 2017, 'Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA/ASCO/ASTRO/SUO Guideline', Journal of Urology. https://doi.org/10.1016/j.juro.2017.04.086
Chang, Sam S. ; Bochner, Bernard H. ; Chou, Roger ; Dreicer, Robert ; Kamat, Ashish M. ; Lerner, Seth P. ; Lotan, Yair ; Meeks, Joshua J. ; Michalski, Jeff M. ; Morgan, Todd M. ; Quale, Diane Z. ; Rosenberg, Jonathan E. ; Zietman, Anthony L. ; Holzbeierlein, Jeffrey M. / Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer : AUA/ASCO/ASTRO/SUO Guideline. In: Journal of Urology. 2017.
@article{3ccd8f17e85d419abf8ed96dac0b0597,
title = "Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA/ASCO/ASTRO/SUO Guideline",
abstract = "Purpose: This multidisciplinary, evidence-based guideline for clinically non-metastatic muscle-invasive bladder cancer focuses on the evaluation, treatment and surveillance of muscle-invasive bladder cancer guided toward curative intent. Materials and Methods: A systematic review utilizing research from the Agency for Healthcare Research and Quality as well as additional supplementation by the authors and consultant methodologists was used to develop the guideline. Evidence-based statements were based on body of evidence strengths Grade A, B or C and were designated as Strong, Moderate and Conditional Recommendations with additional statements presented in the form of Clinical Principles or Expert Opinions. Results: For the first time for any type of malignancy, the American Urological Association, American Society of Clinical Oncology, American Society for Radiation Oncology and Society of Urologic Oncology have formulated an evidence-based guideline based on a risk-stratified clinical framework for the management of muscle-invasive urothelial bladder cancer. This document is designed to be used in conjunction with the associated treatment algorithm. Conclusions: The intensity and scope of care for muscle-invasive bladder cancer should focus on the patient, disease and treatment response characteristics. This guideline attempts to improve a clinician's ability to evaluate and treat each patient, but higher quality evidence in future trials will be essential to improve level of care for these patients.",
keywords = "Cystectomy, Drug therapy, Radiotherapy, Urinary bladder neoplasms",
author = "Chang, {Sam S.} and Bochner, {Bernard H.} and Roger Chou and Robert Dreicer and Kamat, {Ashish M.} and Lerner, {Seth P.} and Yair Lotan and Meeks, {Joshua J.} and Michalski, {Jeff M.} and Morgan, {Todd M.} and Quale, {Diane Z.} and Rosenberg, {Jonathan E.} and Zietman, {Anthony L.} and Holzbeierlein, {Jeffrey M.}",
year = "2017",
doi = "10.1016/j.juro.2017.04.086",
language = "English (US)",
journal = "Journal of Urology",
issn = "0022-5347",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer

T2 - AUA/ASCO/ASTRO/SUO Guideline

AU - Chang, Sam S.

AU - Bochner, Bernard H.

AU - Chou, Roger

AU - Dreicer, Robert

AU - Kamat, Ashish M.

AU - Lerner, Seth P.

AU - Lotan, Yair

AU - Meeks, Joshua J.

AU - Michalski, Jeff M.

AU - Morgan, Todd M.

AU - Quale, Diane Z.

AU - Rosenberg, Jonathan E.

AU - Zietman, Anthony L.

AU - Holzbeierlein, Jeffrey M.

PY - 2017

Y1 - 2017

N2 - Purpose: This multidisciplinary, evidence-based guideline for clinically non-metastatic muscle-invasive bladder cancer focuses on the evaluation, treatment and surveillance of muscle-invasive bladder cancer guided toward curative intent. Materials and Methods: A systematic review utilizing research from the Agency for Healthcare Research and Quality as well as additional supplementation by the authors and consultant methodologists was used to develop the guideline. Evidence-based statements were based on body of evidence strengths Grade A, B or C and were designated as Strong, Moderate and Conditional Recommendations with additional statements presented in the form of Clinical Principles or Expert Opinions. Results: For the first time for any type of malignancy, the American Urological Association, American Society of Clinical Oncology, American Society for Radiation Oncology and Society of Urologic Oncology have formulated an evidence-based guideline based on a risk-stratified clinical framework for the management of muscle-invasive urothelial bladder cancer. This document is designed to be used in conjunction with the associated treatment algorithm. Conclusions: The intensity and scope of care for muscle-invasive bladder cancer should focus on the patient, disease and treatment response characteristics. This guideline attempts to improve a clinician's ability to evaluate and treat each patient, but higher quality evidence in future trials will be essential to improve level of care for these patients.

AB - Purpose: This multidisciplinary, evidence-based guideline for clinically non-metastatic muscle-invasive bladder cancer focuses on the evaluation, treatment and surveillance of muscle-invasive bladder cancer guided toward curative intent. Materials and Methods: A systematic review utilizing research from the Agency for Healthcare Research and Quality as well as additional supplementation by the authors and consultant methodologists was used to develop the guideline. Evidence-based statements were based on body of evidence strengths Grade A, B or C and were designated as Strong, Moderate and Conditional Recommendations with additional statements presented in the form of Clinical Principles or Expert Opinions. Results: For the first time for any type of malignancy, the American Urological Association, American Society of Clinical Oncology, American Society for Radiation Oncology and Society of Urologic Oncology have formulated an evidence-based guideline based on a risk-stratified clinical framework for the management of muscle-invasive urothelial bladder cancer. This document is designed to be used in conjunction with the associated treatment algorithm. Conclusions: The intensity and scope of care for muscle-invasive bladder cancer should focus on the patient, disease and treatment response characteristics. This guideline attempts to improve a clinician's ability to evaluate and treat each patient, but higher quality evidence in future trials will be essential to improve level of care for these patients.

KW - Cystectomy

KW - Drug therapy

KW - Radiotherapy

KW - Urinary bladder neoplasms

UR - http://www.scopus.com/inward/record.url?scp=85025105329&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85025105329&partnerID=8YFLogxK

U2 - 10.1016/j.juro.2017.04.086

DO - 10.1016/j.juro.2017.04.086

M3 - Article

JO - Journal of Urology

JF - Journal of Urology

SN - 0022-5347

ER -